IDH1 and acute myeloid leukemia: Ivosidenib, an oral IDH1 inhibitor, was shown to augment 12‐month EFS (37% vs. 12%; HR 0.33 95% CI 0.16–0.69, p = 0.002) and improve OS (24.0 vs. 7.9 months; HR 0.44, 95% CI 0.27–0.73, p = 0.001) in a randomized, placebo controlled phase III clinical trial investigating newly diagnosed IDH1mut AML patients.104